Chemical combination effects predict connectivity in biological systems
Open accessThe DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Abstract
Efforts to construct therapeutically useful models of biological systems require large and diverse sets of data on functional connections between their components. Here we show that cellular responses to combinations of chemicals reveal how their biological targets are connected. Simulations of pathways with pairs of inhibitors at varying doses predict distinct response surface shapes that are reproduced in a yeast experiment, with further support from a larger screen using human tumour cells. The response morphology yields detailed connectivity constraints between nearby targets, and synergy profiles across many combinations show relatedness between targets in the whole network. Constraints from chemical combinations complement genetic studies, because they probe different cellular components and can be applied to disease models that are not amenable to mutagenesis. Chemical probes also offer increased flexibility, as they can be continuously dosed, temporally controlled, and readily combined. After extending this initial study to cover a wider range of combination effects and pathway topologies, chemical combinations may be used to refine network models or to identify novel targets. This response surface methodology may even apply to non-biological systems where responses to targeted perturbations can be measured.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“combinations of chemical agents (or manipulations such as those of transcription factors that affect multiple steps in a pathway [1906] or modulation of multiple gene products [2311], or both [2312,2313]) will be far more efficacious, for instance in modulating iron-catalysed oxidative stress and its sequelae, than will be the use of 'magic bullet' single agents.”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1707]
Experimental — accuracy not yet measuredIn the citing paper
“and that on general grounds [1706-1708,2142] such a strategy (for instance of combining a cell-permeable iron chelator with a cell-permeable antioxidant) might be expected to give a synergistic response.”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1707]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Numerical recipes in C: the art of scientific computing
(1993) · Choice Reviews Online · doi:10.5860/choice.30-5638 · Cited by 17,933
David, F. N., & Tukey, J. W. (1977) · Biometrics · doi:10.2307/2529486 · Cited by 12,708
Network motifs: simple building blocks of complex networks.
Milo, R., Shen-Orr, S., Itzkovitz, S., Kashtan, N., Chklovskii, D., & Alon, U. (2002) · Science · doi:10.1126/science.298.5594.824 · Cited by 7,368 · cited 2×
“Finally, because the simulated combination responses were insensitive to the reaction details, this methodology may even be extendable to non-biological network problems where responses to targeted perturbations can be measured (Milo et al , 2002).”
Quantitative analysis of complex protein mixtures using isotope-coded affinity tags
Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., & Aebersold, R. (1999) · Nature Biotechnology · doi:10.1038/13690 · Cited by 4,683 · cited 1×
“…Saccharomyces cerevisiae (Zhang et al , 2005), which are built upon protein–DNA (Lee et al , 2002) and protein–protein (Ho et al , 2002) associations, supplemented by correlated changes in gene expression (Hughes et al , 2000) or protein abundances (Gygi et al , 1999) under differing conditions.”
BioGRID: a general repository for interaction datasets
Stark, C. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj109 · Cited by 3,960 · cited 2×
“The observed synergies between sterol inhibitors are reflected in homozygous synthetic lethalities (Stark et al , 2006) that are internal to the pathway, and rapamycin’s synergy with terbinafine agrees with the reported interaction between TOR1 and ERG1.”
Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry
Ho, Y., Gruhler, A., Heilbut, A., Bader, G. D., Moore, L., Adams, S.-L., Millar, A., Taylor, P., Bennett, K., Boutilier, K., et al. (2002) · Nature · doi:10.1038/415180a · Cited by 3,601
Self-citationIdentification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Transcriptional Regulatory Networks in Saccharomyces cerevisiae
Lee, T. I., Rinaldi, N. J., Robert, F., Odom, D. T., Bar-Joseph, Z., Gerber, G. K., Hannett, N. M., Harbison, C. T., Thompson, C. M., Simon, I., et al. (2002) · Science · doi:10.1126/science.1075090 · Cited by 2,956
Functional Discovery via a Compendium of Expression Profiles
Hughes, T. R., Marton, M. J., Jones, A. R., Roberts, C. J., Stoughton, R., Armour, C. D., Bennett, H. A., Coffey, E., Dai, H., He, Y. D., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00015-5 · Cited by 2,533
The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C
Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., & Loriolle, F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98476-0 · Cited by 2,456
THE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419
Global Mapping of the Yeast Genetic Interaction Network
Tong, A. H. Y., Lesage, G., Bader, G. D., Ding, H., Xu, H., Xin, X., Young, J., Berriz, G. F., Brost, R. L., Chang, M., et al. (2004) · Science · doi:10.1126/science.1091317 · Cited by 2,095
Crimins, F. (2003) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-003-0001-6 · Cited by 2,000
A N EW A PPROACH TO D ECODING L IFE : Systems Biology
Ideker, T., Galitski, T., & Hood, L. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.343 · Cited by 1,664 · cited 2×
“Systems Biology involves the iterative construction of such models (Ideker et al , 2001), and may eventually improve the understanding of diseases using in silico simulations.”
A genomic regulatory network for development
Davidson, E. H., Rast, J. P., Oliveri, P., Ransick, A., Calestani, C., Yuh, C.-H., Minokawa, T., Amore, G., Hinman, V., Arenas-Mena, C., et al. (2002) · Science · doi:10.1126/science.1069883 · Cited by 1,567 · cited 1×
“Living organisms are built of interacting components, whose function and dysfunction can be described through dynamic network models (Davidson et al , 2002).”
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Ermentrout, B. (2002) · Society for Industrial and Applied Mathematics eBooks · doi:10.1137/1.9780898718195 · Cited by 1,236
Ermentrout, B. (1987) · Cited by 1,124
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Self-citationA physical and functional map of the human TNF-α/NF-κB signal transduction pathway
Bouwmeester, T., Bauch, A., Ruffner, H., Angrand, P.-O., Bergamini, G., Croughton, K., Cruciat, C., Eberhard, D., Gagneur, J., Ghidelli, S., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1086 · Cited by 1,029
Schoeberl, B., Eichler-Jonsson, C., Gilles, E. D., & Müller, G. (2002) · Nature Biotechnology · doi:10.1038/nbt0402-370 · Cited by 950
Rottlerin, a Novel Protein Kinase Inhibitor
Gschwendt, M., Muller, H. J., Kielbassa, K., Zang, R., Kittstein, W., Rincke, G., & Marks, F. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1199 · Cited by 841
The efficiency of multi-target drugs: the network approach might help drug design
CSERMELY, P., AGOSTON, V, & PONGOR, S. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.02.007 · Cited by 803 · cited 1×
“Deviations from Loewe additivity are usually quantified using the combination index (Chou and Talalay, 1983) CI ¼ ( X / X I ) þ ( Y / Y I ), which is essentially a ratio of total effective drug dose (combination versus single agents) required to achieve a given effect level.”
Multicomponent therapeutics for networked systems
Keith, C. T., Borisy, A. A., & Stockwell, B. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1609 · Cited by 769 · cited 1×
“We have previously reported an approach for high-throughput dose-& matrix screening of chemical combinations (Borisy et al , 2003; Keith et al , 2005; Zimmermann et al , 2007) in cell-based assays that preserve disease-relevant biological connections.”
Self-citationParsons, A. B., Brost, R. L., Ding, H., Li, Z., Zhang, C., Sheikh, B., Brown, G. W., Kane, P. M., Hughes, T. R., & Boone, C. (2004) · Nature Biotechnology · doi:10.1038/nbt919 · Cited by 675
Multidimensional Drug Profiling By Automated Microscopy
Perlman, Z. E., Slack, M. D., Feng, Y., Mitchison, T. J., Wu, L. F., & Altschuler, S. J. (2004) · Science · doi:10.1126/science.1100709 · Cited by 660
Altered Growth of Human Colon Cancer Cell Lines Disrupted at Activated Ki- ras
Shirasawa, S., Furuse, M., Yokoyama, N., & Sasazuki, T. (1993) · Science · doi:10.1126/science.8465203 · Cited by 620
Systematic discovery of multicomponent therapeutics
Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620 · cited 1×
“We have previously reported an approach for high-throughput dose-& matrix screening of chemical combinations (Borisy et al , 2003; Keith et al , 2005; Zimmermann et al , 2007) in cell-based assays that preserve disease-relevant biological connections.”
Self-citationAnalysis of combined drug effects: a new look at a very old problem
Chou, T.-C., & Talalay, P. (1983) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(83)90490-x · Cited by 619
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
Nebbioso, A., Clarke, N., Voltz, E., Germain, E., Ambrosino, C., Bontempo, P., Alvarez, R., Schiavone, E. M., Ferrara, F., Bresciani, F., et al. (2005) · Nature Medicine · doi:10.1038/nm1161 · Cited by 610
Modular epistasis in yeast metabolism
Segrè, D., DeLuna, A., Church, G. M., & Kishony, R. (2005) · Nature Genetics · doi:10.1038/ng1489 · Cited by 575 · cited 1×
“There was more agreement between our simulation results and a prior flux balance analysis (FBA) of the yeast metabolic network”
The expected effect of a combination of agents: the general solution
Berenbaum, M. C. (1985) · Journal of Theoretical Biology · doi:10.1016/s0022-5193(85)80176-4 · Cited by 523
Chemogenomic profiling: Identifying the functional interactions of small molecules in yeast
Giaever, G., Flaherty, P., Kumm, J., Proctor, M., Nislow, C., Jaramillo, D. F., Chu, A. M., Jordan, M. I., Arkin, A. P., & Davis, R. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307490100 · Cited by 504
Lum, P. Y., Armour, C. D., Stepaniants, S. B., Cavet, G., Wolf, M. K., Butler, J. S., Hinshaw, J. C., Garnier, P., Prestwich, G. D., Leonardson, A., et al. (2004) · Cell · doi:10.1016/s0092-8674(03)01035-3 · Cited by 481
Common and Distinct Elements in Cellular Signaling via EGF and FGF Receptors
Schlessinger, J. (2004) · Science · doi:10.1126/science.1105396 · Cited by 443
Okada, T., Sakuma, L., Fukui, Y., Hazeki, O., & Ui, M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41900-4 · Cited by 438
Drug resistance in cancer: Principles of emergence and prevention
Komarova, N. L., & Wodarz, D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501870102 · Cited by 414
Test of synergistic interactions among deleterious mutations in bacteria
Elena, S. F., & Lenski, R. E. (1997) · Nature · doi:10.1038/37108 · Cited by 404
Alendronate Is a Specific, Nanomolar Inhibitor of Farnesyl Diphosphate Synthase
Bergstrom, J. D., Bostedor, R. G., Masarachia, P. J., Reszka, A. A., & Rodan, G. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1502 · Cited by 402
Strategies for reversing drug resistance
Fojo, T., & Bates, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206951 · Cited by 357
Famili, I., Förster, J., Nielsen, J., & Palsson, B. O. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2235812100 · Cited by 353 · cited 1×
“Another approach would be to systematically explore perturbations of an existing biological network, such as S. cerevisiae metabolism (Famili et al , 2003), and to model drug inhibition by partially restricting the reaction rates at metabolic enzymes, essentially the Segre` et al ’s FBA for partial…”
Functional classification of drugs by properties of their pairwise interactions
Yeh, P., Tschumi, A. I., & Kishony, R. (2006) · Nature Genetics · doi:10.1038/ng1755 · Cited by 350
Douglas, C. M., D'Ippolito, J. A., Shei, G. J., Meinz, M., Onishi, J., Marrinan, J. A., Li, W., Abruzzo, G. K., Flattery, A., Bartizal, K., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2471 · Cited by 344
Identifying off-target effects and hidden phenotypes of drugs in human cells
MacDonald, M. L., Lamerdin, J., Owens, S., Keon, B. H., Bilter, G. K., Shang, Z., Huang, Z., Yu, H., Dias, J., Minami, T., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio790 · Cited by 293
Targeted selection of recombinant clones through gene dosage effects.
Rine, J., Hansen, W., Hardeman, E., & Davis, R. W. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.22.6750 · Cited by 252
High-resolution yeast phenomics resolves different physiological features in the saline response
Warringer, J., Ericson, E., Fernandez, L., Nerman, O., & Blomberg, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2435976100 · Cited by 237
Die quantitativen Probleme der Pharmakologie
Loewe, S. (1928) · Ergebnisse der Physiologie · doi:10.1007/bf02322290 · Cited by 229
Davis, P. D., Elliott, L. H., Harris, W., Hill, C. H., Hurst, S. A., Keech, E., Kumar, M. K. H., Lawton, G., Nixon, J. S., & Wilkinson, S. E. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00084a004 · Cited by 213
Motifs, themes and thematic maps of an integrated Saccharomyces cerevisiaeinteraction network
Zhang, L. V., King, O. D., Wong, S. L., Goldberg, D. S., Tong, A. H., Lesage, G., Andrews, B., Bussey, H., Boone, C., & Roth, F. P. (2005) · Journal of Biology · doi:10.1186/jbiol23 · Cited by 190
Inhibitors of protein kinase C
Gordge, P. C., & Jonathan Ryves, W. (1994) · Cellular Signalling · doi:10.1016/0898-6568(94)90020-5 · Cited by 160
Antifungal Agents Used for Deep-Seated Mycotic Infections
Terrell, C. L., & Hughes, C. E. (1992) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60281-x · Cited by 156
Fox, T., Coll, J. T., Xie, X., Ford, P. J., Germann, U. A., Porter, M. D., Pazhanisamy, S., Fleming, M. A., Galullo, V., Su, M. S. S., et al. (1998) · Protein Science · doi:10.1002/pro.5560071102 · Cited by 150
Environmental stresses can alleviate the average deleterious effect of mutations
Kishony, R., & Leibler, S. (2003) · Journal of Biology · doi:10.1186/1475-4924-2-14 · Cited by 139
Lorenz, R. T., & Parks, L. W. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.9.1660 · Cited by 104
Systematic quantification of gene interactions by phenotypic array analysis
Hartman, J. L., & Tippery, N. P. (2004) · Genome Biology · doi:10.1186/gb-2004-5-7-r49 · Cited by 67
Yano, H., Agatsuma, T., Nakanishi, S., Saitoh, Y., Fukui, Y., Nonomura, Y., & Matsuda, Y. (1995) · Biochemical Journal · doi:10.1042/bj3120145 · Cited by 62
Haggarty, S. J., Clemons, P. A., & Schreiber, S. L. (2003) · Journal of the American Chemical Society · doi:10.1021/ja035413p · Cited by 61
Gardner, R. G., Shan, H., Matsuda, S. P. T., & Hampton, R. Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007888200 · Cited by 54
A System of Models for the Action of Drugs Applied Singly or Jointly to Biological Organisms
Ashford, J. R., & Cobby, J. M. (1974) · Biometrics · doi:10.2307/2529614 · Cited by 53
New potential targets for antifungal development
Wills, E. A., Redinbo, M. R., Perfect, J. R., & Poeta, M. D. (2000) · Emerging Therapeutic Targets · doi:10.1517/14728222.4.3.265 · Cited by 44
The role of transforming growth factor alpha in determining growth factor independence.
Awwad, R. A., Sergina, N. V., Yang, H.-S., Ziober, B. L., Willson, J. K. V., Zborowska, E., Humphrey, L. E., Fan, R. S., Ko, T. C., Brattain, M. G., et al. (2003) · PubMed · Cited by 40
Global architecture of genetic interactions on the protein network
Ozier, O. W., Amin, N., & Ideker, T. (2003) · Nature Biotechnology · doi:10.1038/nbt0503-490 · Cited by 37
Review of the application of response surface methodology in the combination therapy of cancer.
Carter, W. H., & Gl, W. (1986) · PubMed · Cited by 36
Enzyme kinetics and combination chemotherapy: An appraisal of current concepts
Harrap, K. R., & Jackson, R. (1975) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(75)90009-6 · Cited by 17
Jackson, R. (1993) · PubMed · Cited by 16
Fielding, A. H. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511607493.003 · Cited by 2
Cited by
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
“Consider an extreme scenario in which the drug combination barely reaches significance (e.g., P = 0.049) and its individual components narrowly failed to reach significance (e.g., P = 0.051).”
BackgroundMethodInfluentialCombinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short III, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 938
Self-citationStructure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Metadata
- Authors
- Lehár, J., Zimmermann, G. R., Krueger, A. S., Molnar, R. A., Ledell, J. T., Heilbut, A. M., Short, G. F., Giusti, L. C., Nolan, G. P., Magid, O. A., Lee, M. S., Borisy, A. A., Stockwell, B. R., & Keith, C. T.
- Affiliations
- Boston University (US)
- Columbia University (US)
- Corresponding author
- Lehár, Joseph
- Venue
- Molecular Systems Biology
- Published
- 2007-02-27
- Volume
- 3
- Issue
- 1
- Pages
- 80-80
- ISSN
- 1744-4292 (ISSN-L)
- PMC
- PMC1828746
- OpenAlex
- W1975728616
- Cited by
- 275
- References
- 68
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 15 · 2023: 15 · 2022: 9 · 2021: 14 · 2020: 11 · 2019: 17 · 2018: 18 · 2017: 11 · 2016: 15 · 2015: 18 · 2014: 22 · 2013: 14 · 2012: 13
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Systems Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- OpenBU (Boston University) (submittedVersion)
- Funders
- Burroughs Wellcome Fund
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- synergistic effect, response surface, pathway modeling, inhibitors, dose-response relationship, yeast, cancer cells, network inference, chemical probes
- MeSH terms
- Computer Simulation, Drug Combinations, Drug Synergism, Humans, Models, Biological, Saccharomyces cerevisiae, Sterols, Models, Statistical, Gene Expression Regulation, Fungal, HCT116 Cells, Systems Biology, Metabolic Networks and Pathways
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.